xofigo(Radium Ra 223 dichloride)Medication DetailsBayer HealthCare Pharmaceuticals Inc.Usage: Xofigo is indicated for treating patients with castration-resistant prostate cancer who have symptomatic bone metastases and no known visceral metastatic disease.Medication DetailsDrug Interactions